Angel Arnaout, MD, MSc; Christina Catley, PhD; Christopher M. Booth, MD; et al.
free access
JAMA Oncol. 2015;1(9):1238-1250. doi:10.1001/jamaoncol.2015.3018
This population-based cohort study used administrative heath care databases in Ontario, Canada, and determined that preoperative breast MRI use is associated with a significant increase in ancillary investigations, wait time to surgery, mastectomies, and contralateral prophylactic mastectomies.
-
Editorial
Rethinking Preoperative Breast Magnetic Resonance Imaging
Habib Rahbar, MD; Constance D. Lehman, MD, PhD
JAMA Oncol
Joanne Armstrong, MD, MPH; Michele Toscano, MS; Nancy Kotchko, MA; et al.
open access
JAMA Oncol. 2015;1(9):1251-1260. doi:10.1001/jamaoncol.2015.3048
This survey study found that despite improved knowledge, understanding, and satisfaction among patients who receive genetic counseling provided by a genetics clinician, as well as guidelines emphasizing genetic counseling, most US women undergoing BRCA testing do not receive this service.
Sindy Magnan, MD, MSc, FRCPC; Ryan Zarychanski, MD, MSc, FRCPC; Laurie Pilote, MD; et al.
free access
JAMA Oncol. 2015;1(9):1261-1269. doi:10.1001/jamaoncol.2015.2895
This systematic review and meta-analysis of 15 randomized clinical trials (6856 patients) finds that overall survival in intermittent androgen deprivation therapy for prostate cancer was not inferior to continuous therapy, and some quality-of-life criteria seemed improved with intermittent therapy.
Sant P. Chawla, MD; Zsuzsanna Papai, MD; Guzel Mukhametshina, MD; et al.
open access
JAMA Oncol. 2015;1(9):1272-1280. doi:10.1001/jamaoncol.2015.3101
This international, multicenter, phase 2b, open-label, randomized study evaluated the efficacy and safety of treatment with aldoxorubicin vs doxorubicin in patients with previously untreated locally advanced, unresectable, or metastatic soft-tissue sarcoma.
-
Invited Commentary
Aldoxorubicin in Sarcoma: Teaching an Old Drug New Tricks
Rashmi Chugh, MD; Scott M. Schuetze, MD, PhD
JAMA Oncol
Marcus G. K. Cumberbatch, MBBS, BSc, MSc; Angela Cox, PhD; Dawn Teare, PhD; et al.
free access
JAMA Oncol. 2015;1(9):1282-1290. doi:10.1001/jamaoncol.2015.3209
This systematic review and meta-analysis identifies contemporary occupations associated with increased incidence of risk of bladder cancer risk; workers with aromatic amine exposure have the highest incidence, while those exposed to PAHs and heavy metals have the greatest mortality.
-
Invited Commentary
The Need for Further Preventive Measures for Occupational Bladder Cancer
Elisabete Weiderpass, MD, MSc, PhD; Harri Vainio, MD, PhD
JAMA Oncol
Daniel A. Goldstein, MD; Qiushi Chen, BSc; Turgay Ayer, PhD; et al.
free access
JAMA Oncol. 2015;1(9):1293-1300. doi:10.1001/jamaoncol.2015.3316
This cost-effectiveness analysis of the SQUIRE trial findings and others evaluates incremental costs and patient life expectancies associated with adding necitumumab to standard chemotherapy as first-line treatment of metastatic squamous cell lung cancer.
-
Invited Commentary
Value-Based Cancer Care and the Excessive Cost of Drugs
Benjamin Djulbegovic, MD, PhD
JAMA Oncol
David G. Pfister, MD; David M. Rubin, BS; Elena B. Elkin, PhD, MPA; et al.
open access
JAMA Oncol. 2015;1(9):1303-1310. doi:10.1001/jamaoncol.2015.3151
This analysis and comparison of cancer treatment outcomes gleaned from 2 types of database records, those including and those not including staging information, finds that records without staging data might be adequate to accurately measure, at the hospital level, cancer survival outcomes.
Takeo Fujii, MD, MPH; Fanny Le Du, MD; Lianchun Xiao, MS; et al.
free access
JAMA Oncol. 2015;1(9):1311-1318. doi:10.1001/jamaoncol.2015.3062
This systematic review uses data from multiple medical databases and other sources to identify that sequential anthracycline-cyclophosphamide and taxane is likely the most effective adjuvant therapy for early-stage breast cancer.